A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer (FALCON)

Clinical Trial ID NCT00653939

Rank	Title	Journal	Year	PubWeight™‹?›
1	Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.	N Engl J Med	2006	34.52
2	The biology of vascular endothelial growth factor.	Endocr Rev	1997	13.70
3	Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.	Science	2006	4.79
4	Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma.	Cancer Res	2001	2.17
5	Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.	Mol Pharmacol	1988	1.54
6	Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.	Anticancer Res	1999	1.31
7	Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.	Int J Cancer	2002	1.25
8	Anti-angiogenesis therapies: their potential in cancer management.	Onco Targets Ther	2010	1.05
9	Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization.	Bioorg Med Chem	2011	0.99
10	The continuing search for antitumor agents from higher plants.	Phytochem Lett	2010	0.94
11	Synthesis of N(4)-(substituted phenyl)-N(4)-alkyl/desalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines and identification of new microtubule disrupting compounds that are effective against multidrug resistant cells.	Bioorg Med Chem	2012	0.78